medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2026-5-54-60medalphabet-5019Research ArticleСтатьиСостояние жировой ткани у пациентов с воспалительными заболеваниями кишечника: проблемы диагностики и клиническое значениеAdipose tissue status in patients with inflammatory bowel disease: diagnostic challenges and clinical significanceТабакчиО. Э.TabakchiO. E.

Табакчи Ольга Эриковна, аспирант кафедры госпитальной терапии

AuthorID: 1262535

Республика Татарстан, Казань

Tabakchi Olga E., graduate student at Dept of Hospital Therapy

AuthorID: 1262535

Kazan

olya-akchurina@mail.ruhttps://orcid.org/0000-0003-2102-0142МухаметоваД. Д.MukhametovaD. D.

Мухаметова Диляра Дамировна, к. м. н., доцент кафедры госпитальной терапии

AuthorID: 953220

Республика Татарстан, Казань

Mukhametova Dilyara D., PhD Med Sci, associate professor at Dept of Hospital Therapy

AuthorID: 953220

Kazan

muhdilyara@gmail.comhttps://orcid.org/0000-0002-9120-3588БодрягинаЕ. С.BodryaginaE. S.

Бодрягина Евгения Сергеевна, к. м. н., доцент кафедры госпитальной терапии

AuthorID: 824803

Республика Татарстан, Казань

Bodryagina Evgenia S., PhD Med Sci, associate professor at Dept of Hospital Therapy

AuthorID: 824803

Kazan

evgenia.bodryagina@kazangmu.ruЧереминаН. А.ChereminaN. A.

Черемина Наталья Александровна, врач-гастроэнтеролог отделения гастроэнтерологии

AuthorID: 1148537

Республика Татарстан, Казань

Cheremina Natalia A., gastroenterologist at Dept of Gastroenterology

Kazan

doctornat@mail.ruhttps://orcid.org/0000-0003-1270-5457ОдинцоваА. Х.OdintsovaA. Kh.

Одинцова Альфия Харисовна, к. м. н., заведующая отделением гастроэнтерологии

Республика Татарстан, Казань

Odintsova Alfiya Kh., PhD Med Sci, head of Gastroenterology Dept.

Kazan

odincovaa@yandex.ruhttps://orcid.org/0000-0001-7069-2725АбдулганиеваД. И.AbdulganievaD. I.

Абдулганиева Диана Ильдаровна, д. м. н., профессор, зав. кафедрой госпитальной терапии

AuthorID: 252778

Республика Татарстан, Казань

Abdulganieva Diana I., Dr Med Sci (habil.), professor, head of Dept of Hospital Therapy

AuthorID: 252778

Kazan

diana.abdulganieva@kazangmu.ruФГБОУ ВО «Казанский государственный медицинский университет» Минздрава РоссииРоссияKazan State Medical UniversityRussian FederationГАУЗ «Республиканская клиническая больница Министерства здравоохранения Республики Татарстан»РоссияRepublican Clinical Hospital of the Ministry of Health of the Republic of TatarstanRussian Federation20260505202605Гастроэнтерология и диетология (1)5460Copyright © Табакчи О.Э., Мухаметова Д.Д., Бодрягина Е.С., Черемина Н.А., Одинцова А.Х., Абдулганиева Д.И., 20262026Табакчи О.Э., Мухаметова Д.Д., Бодрягина Е.С., Черемина Н.А., Одинцова А.Х., Абдулганиева Д.И.Tabakchi O.E., Mukhametova D.D., Bodryagina E.S., Cheremina N.A., Odintsova A.K., Abdulganieva D.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/5019Цель

Цель. Сравнить различные методы оценки жировой ткани (индекс массы тела (ИМТ), биоимпедансный анализ (БИА), ультразвуковое исследование (УЗИ)) у пациентов с воспалительными заболеваниями кишечника (ВЗК).

Материал и методы

Материал и методы. В исследование включены 136 пациентов с ВЗК (62 с язвенным колитом, 74 с болезнью Крона) и 30 человек в группу контроля. Всем выполнены антропометрия, динамометрия, БИА и УЗИ жировой ткани.

Результаты

Результаты. По данным ИМТ, избыточная масса тела и ожирение выявлены у 28,7 % пациентов с ВЗК. БИА показал избыток жировой массы у 31,9 % пациентов, при этом из них у 30,2 % ИМТ был в пределах нормы. УЗИ выявило увеличение жировой ткани у 47,3 % пациентов, позволив дифференцировать типы ожирения. У 44 % пациентов с нормальным ИМТ по данным УЗИ обнаружен избыток жира. Выявлена отрицательная корреляция доли жировой массы с показателями динамометрии (r= –0,363; p<0,001).

Выводы

Выводы. Существует необходимость включения инструментальных методов оценки состава тела в алгоритмы обследования пациентов с ВЗК для своевременной коррекции нутритивного статуса и профилактики осложнений. Высокая распространенность избытка жировой массы и ее связь со снижением мышечной силы (динапения) обосновывают необходимость скрининга саркопенического ожирения у пациентов с ВЗК.

The aim of this study

The aim of this study. To compare different methods of adipose tissue assessment (body mass index (BMI), bioelectrical impedance analysis (BIA), ultrasound (US)) in patients with inflammatory bowel disease (IBD).

Materials and methods

Materials and methods. The study included 136 patients with IBD (62 with ulcerative colitis, 74 with Crohn's disease) and 30 control subjects. All participants underwent anthropometry (BMI, circumferences), handgrip strength measurement, BIA, and adipose tissue ultrasound according to a standardized protocol.

Results

Results. According to BMI, overweight and obesity were found in 28.7 % of IBD patients. BIA revealed excess fat mass in 31.9 % of patients; notably, 30.2 % of these individuals had a normal BMI. Ultrasound detected increased adipose tissue in 47.3 % of patients, allowing for differentiation of obesity types. Excess fat was found by ultrasound in 44 % of patients with normal BMI. A negative correlation was found between fat mass percentage and handgrip strength (r= –0.363; p<0.001).

Conclusions

Conclusions. There is a need to include instrumental methods for assessing body composition in the examination algorithms for patients with IBD for timely correction of nutritional status and prevention of complications. The high prevalence of excess fat mass and its association with decreased muscle strength (dynapenia) justify the need for screening for sarcopenic obesity in patients with IBD.

воспалительные заболевания кишечникаожирениеиндекс массы телабиоимпедансный анализультразвуковая диагностикадинапениясаркопеническое ожирениеinflammatory bowel diseaseobesitybody mass indexbioimpedance analysisultrasound diagnosticsdynapeniasarcopenic obesityReferencesSingh S, Dulai PS, Zarrinpar A, Ramamoorthy S, Sandborn WJ. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2017; 14 (2): 110–121. DOI: 10.1038/nrgastro.2016.181Singh S, Dulai PS, Zarrinpar A, Ramamoorthy S, Sandborn WJ. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2017; 14 (2): 110–121. DOI: 10.1038/nrgastro.2016.181Nic Suibhne T, Raftery TC, McMahon O, Walsh C, O'Morain C, O'Sullivan M. High prevalence of overweight and obesity in adults with Crohn's disease: associations with disease and lifestyle factors. J Crohns Colitis. 2013; 7 (7): e241–e248. DOI: 10.1016/j.crohns.2012.09.009Nic Suibhne T, Raftery TC, McMahon O, Walsh C, O'Morain C, O'Sullivan M. High prevalence of overweight and obesity in adults with Crohn's disease: associations with disease and lifestyle factors. J Crohns Colitis. 2013; 7 (7): e241–e248. DOI: 10.1016/j.crohns.2012.09.009Barazzoni R, Bischoff S, Boirie Y, et al. Sarcopenic Obesity: Time to Meet the Challenge. Obes Facts. 2018; 11 (4): 294–305. DOI: 10.1159/000490361Barazzoni R, Bischoff S, Boirie Y, et al. Sarcopenic Obesity: Time to Meet the Challenge. Obes Facts. 2018; 11 (4): 294–305. DOI: 10.1159/000490361Hass DJ, Brensinger CM, Lewis JD, Lichtenstein GR. The impact of increased body mass index on the clinical course of Crohn's disease. Clin Gastroenterol Hepatol. 2006; 4 (4): 482–488. DOI: 10.1016/j.cgh.2005.12.015Hass DJ, Brensinger CM, Lewis JD, Lichtenstein GR. The impact of increased body mass index on the clinical course of Crohn's disease. Clin Gastroenterol Hepatol. 2006; 4 (4): 482–488. DOI: 10.1016/j.cgh.2005.12.015Flores A, Burstein E, Cipher DJ, Feagins LA. Obesity in Inflammatory Bowel Disease: A Marker of Less Severe Disease. Dig Dis Sci. 2015; 60 (8): 2436–2445. DOI: 10.1007/s10620-015-3629-5Flores A, Burstein E, Cipher DJ, Feagins LA. Obesity in Inflammatory Bowel Disease: A Marker of Less Severe Disease. Dig Dis Sci. 2015; 60 (8): 2436–2445. DOI: 10.1007/s10620-015-3629-5Jain A, Nguyen NH, Proudfoot JA. et al. Impact of Obesity on Disease Activity and Patient-Reported Outcomes Measurement Information System (PROMIS) in Inflammatory Bowel Diseases. Am J Gastroenterol. 2019; 114 (4): 630–639. DOI: 10.14309/ajg.0000000000000197Jain A, Nguyen NH, Proudfoot JA. et al. Impact of Obesity on Disease Activity and Patient-Reported Outcomes Measurement Information System (PROMIS) in Inflammatory Bowel Diseases. Am J Gastroenterol. 2019; 114 (4): 630–639. DOI: 10.14309/ajg.0000000000000197Greuter T, Porchet F, Braga-Neto MB. et al. Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: Results from the Swiss inflammatory bowel disease cohort. United European Gastroenterol J. 2020; 8 (10): 1196–1207. DOI: 10.1177/2050640620954556Greuter T, Porchet F, Braga-Neto MB. et al. Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: Results from the Swiss inflammatory bowel disease cohort. United European Gastroenterol J. 2020; 8 (10): 1196–1207. DOI: 10.1177/2050640620954556Moran GW, Dubeau MF, Kaplan GG, Panaccione R, Ghosh S. The increasing weight of Crohn's disease subjects in clinical trials: a hypothesis-generatings time-trend analysis. Inflamm Bowel Dis. 2013; 19 (13): 2949–2956. DOI: 10.1097/ MIB.0b013e31829936a4Moran GW, Dubeau MF, Kaplan GG, Panaccione R, Ghosh S. The increasing weight of Crohn's disease subjects in clinical trials: a hypothesis-generatings time-trend analysis. Inflamm Bowel Dis. 2013; 19 (13): 2949–2956. DOI: 10.1097/ MIB.0b013e31829936a4Бикбавова Г. Р., Драпкина О. М., Ливзан М. А., Лисютенко Н. С., Романюк А. Е. Эффекты динапении и избыточной массы тела у пациентов с язвенным колитом. Терапевтический архив. 2025; 97 (2): 121–127.Bicbavova GR, Drapkina OM, Livzan MA, Lisyutenko NS, Romanyuk AE. Effects of dynapenia and excess body weight in patients with ulcerative colitis. Terapevticheskii Arkhiv (Ter. Arkh.). 2025; 97 (2): 121–127. (In Russ.) https://doi.org/10.26442/00403660.2025.02.203118Biancone L, Mancone R, Biancone L, et al. Obesity and Clinical Characteristics of Inflammatory Bowel Disease. Obes Facts. 2025; 18 (5): 429–444. DOI: 10.1159/000545436Biancone L, Mancone R, Biancone L, et al. Obesity and Clinical Characteristics of Inflammatory Bowel Disease. Obes Facts. 2025; 18 (5): 429–444. DOI: 10.1159/000545436Yarur AJ, Bruss A, Moosreiner A. et al. Higher Intra-Abdominal Visceral Adipose Tissue Mass Is Associated With Lower Rates of Clinical and Endoscopic Remission in Patients With Inflammatory Bowel Diseases Initiating Biologic Therapy: Results of the Constellation Study. Gastroenterology. 2023; 165 (4): 963–975.e5. DOI: 10.1053/j.gastro.2023.06.036Yarur AJ, Bruss A, Moosreiner A. et al. Higher Intra-Abdominal Visceral Adipose Tissue Mass Is Associated With Lower Rates of Clinical and Endoscopic Remission in Patients With Inflammatory Bowel Diseases Initiating Biologic Therapy: Results of the Constellation Study. Gastroenterology. 2023; 165 (4): 963–975.e5. DOI: 10.1053/j.gastro.2023.06.036Eggers KR, Møllegaard KM, Gregersen L, et al. Impact of Obesity on Treatment Response in Patients With Chronic Inflammatory Disease Receiving Biologic Therapy: Secondary Analysis of the Prospective Multicentre BELIEVE Cohort Study. Scand J Immunol. 2025; 101 (6): e70035. DOI: 10.1111/sji.70035Eggers KR, Møllegaard KM, Gregersen L, et al. Impact of Obesity on Treatment Response in Patients With Chronic Inflammatory Disease Receiving Biologic Therapy: Secondary Analysis of the Prospective Multicentre BELIEVE Cohort Study. Scand J Immunol. 2025; 101 (6): e70035. DOI: 10.1111/sji.70035Ezeani C, Mooney J, Ramalingam P, et al. S 1458 A Retrospective Analysis of the Impact of Body Mass Index on Treatment Failure of Ustekinumab Within an Inflammatory Bowel Disease Population (BELT-IBD). Am J Gastroenterol. 2024 Oct; 119 (10S): S 1049–S 1050. DOI: 10.14309/01.ajg.0001035200.19476.24Ezeani C, Mooney J, Ramalingam P, et al. S 1458 A Retrospective Analysis of the Impact of Body Mass Index on Treatment Failure of Ustekinumab Within an Inflammatory Bowel Disease Population (BELT-IBD). Am J Gastroenterol. 2024 Oct; 119 (10S): S 1049–S 1050. DOI: 10.14309/01.ajg.0001035200.19476.24Seminerio JL, Koutroubakis IE, Ramos-Rivers C, et al. Impact of Obesity on the Management and Clinical Course of Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015; 21 (12): 2857–2863. DOI: 10.1097/MIB.0000000000000560Seminerio JL, Koutroubakis IE, Ramos-Rivers C, et al. Impact of Obesity on the Management and Clinical Course of Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015; 21 (12): 2857–2863. DOI: 10.1097/MIB.0000000000000560Stabroth-Akil D, Leifeld L, Pfützer R, Morgenstern J, Kruis W. The effect of body weight on the severity and clinical course of ulcerative colitis. Int J Colorectal Dis. 2015; 30 (2): 237–242. DOI: 10.1007/s00384-014-2051-3Stabroth-Akil D, Leifeld L, Pfützer R, Morgenstern J, Kruis W. The effect of body weight on the severity and clinical course of ulcerative colitis. Int J Colorectal Dis. 2015; 30 (2): 237–242. DOI: 10.1007/s00384-014-2051-3Драпкина О. М., Ангарский Р. К., Рогожкина Е. А., Максимова О. А., Иванова А. А., Зятенкова Е. В., Джиоева О. Н. Российское общество профилактики неинфекционных заболеваний. Ультразвук-ассистированная оценка толщины висцеральной и подкожной жировой ткани. Методические рекомендации. Кардиоваскулярная терапия и профилактика. 2023; 22 (3): 3552.Drapkina O. M., Angarsky R. K., Rogozhkina E. A., Maksimova O. A., Ivanova A. A., Zyatenkova E. V., Dzhioeva O. N. Ultrasound-assisted assessment of visceral and subcutaneous adipose tissue thickness. Methodological guidelines. Cardiovascular Therapy and Prevention. 2023; 22 (3): 3552. (In Russ.). https://doi.org/10.15829/1728-8800-2023-3552Nam K, Lee JY, Ko Y, et al. Impact of Sarcopenia on Clinical Course of Inflammatory Bowel Disease in Korea. Dig Dis Sci. 2023; 68 (6): 2165–2179. DOI: 10.1007/s10620-023-07838-zNam K, Lee JY, Ko Y, et al. Impact of Sarcopenia on Clinical Course of Inflammatory Bowel Disease in Korea. Dig Dis Sci. 2023; 68 (6): 2165–2179. DOI: 10.1007/s10620-023-07838-zMohammadian Khonsari N, Khashayar P, Shahrestanaki E, et al. Normal Weight Obesity and Cardiometabolic Risk Factors: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2022; 13: 857930. Published 2022 Mar 24. DOI: 10.3389/fendo.2022.857930Mohammadian Khonsari N, Khashayar P, Shahrestanaki E, et al. Normal Weight Obesity and Cardiometabolic Risk Factors: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2022; 13: 857930. Published 2022 Mar 24. DOI: 10.3389/fendo.2022.857930Donnelly M, Driever D, Ryan ÉJ, et al. Obesity, Sarcopenia and Myosteatosis: Impact on Clinical Outcomes in the Operative Management of Crohn's Disease. Inflamm Bowel Dis. 2024; 30 (9): 1517–1528. DOI: 10.1093/ibd/izad225Donnelly M, Driever D, Ryan ÉJ, et al. Obesity, Sarcopenia and Myosteatosis: Impact on Clinical Outcomes in the Operative Management of Crohn's Disease. Inflamm Bowel Dis. 2024; 30 (9): 1517–1528. DOI: 10.1093/ibd/izad225Massironi S, Viganò C, Palermo A, et al. Inflammation and malnutrition in inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2023; 8 (6): 579–590. DOI: 10.1016/S 2468-1253 (23) 00011-0Massironi S, Viganò C, Palermo A, et al. Inflammation and malnutrition in inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2023; 8 (6): 579–590. DOI: 10.1016/S 2468-1253 (23) 00011-0Gold SL, Raman M, Sands BE, Ungaro R, Sabino J. Review article: Putting some muscle into sarcopenia-the pathogenesis, assessment and clinical impact of muscle loss in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2023; 57 (11): 1216–1230. DOI: 10.1111/apt.17498Gold SL, Raman M, Sands BE, Ungaro R, Sabino J. Review article: Putting some muscle into sarcopenia-the pathogenesis, assessment and clinical impact of muscle loss in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2023; 57 (11): 1216–1230. DOI: 10.1111/apt.17498Kim H, Kim SE, Sung MK. Sex and Gender Differences in Obesity: Biological, Sociocultural, and Clinical Perspectives. World J Mens Health. 2025; 43 (4): 758–772. DOI: 10.5534/wjmh.250126Kim H, Kim SE, Sung MK. Sex and Gender Differences in Obesity: Biological, Sociocultural, and Clinical Perspectives. World J Mens Health. 2025; 43 (4): 758–772. DOI: 10.5534/wjmh.250126Annunziata G, Verde L, Grillo ARA, et al. Association among measurements obtained using portable ultrasonography with sex, body mass index, and age in a large sample of adult population. J Transl Med. 2025; 23 (1): 236. Published 2025 Feb 27. DOI: 10.1186/s12967-025-06159-1Annunziata G, Verde L, Grillo ARA, et al. Association among measurements obtained using portable ultrasonography with sex, body mass index, and age in a large sample of adult population. J Transl Med. 2025; 23 (1): 236. Published 2025 Feb 27. DOI: 10.1186/s12967-025-06159-1Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007; 116 (1): 39–48. DOI: 10.1161/CIRCULATIONAHA.106.675355Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007; 116 (1): 39–48. DOI: 10.1161/CIRCULATIONAHA.106.675355Neeland IJ, Ross R, Després JP, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 2019; 7 (9): 715–725. DOI: 10.1016/S2213-8587 (19) 30084-1Neeland IJ, Ross R, Després JP, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 2019; 7 (9): 715–725. DOI: 10.1016/S2213-8587 (19) 30084-1Li X, Song FL, He HF, Zeng SM, Feng ZC, Rong PF. Longitudinal computed tomography- based delta-radiomics of visceral adipose tissue predicts infliximab secondary loss of response in Crohn's disease patients. World J Gastroenterol. 2025; 31 (21): 105895. DOI: 10.3748/wjg.v31.i21.105895Li X, Song FL, He HF, Zeng SM, Feng ZC, Rong PF. Longitudinal computed tomography- based delta-radiomics of visceral adipose tissue predicts infliximab secondary loss of response in Crohn's disease patients. World J Gastroenterol. 2025; 31 (21): 105895. DOI: 10.3748/wjg.v31.i21.105895Xiong Z, Wu P, Zhang Y, Chen J, Shen Y, Yu S, Yuan H, He L, Li Z. Radiological biomarkers reflecting visceral fat distribution help distinguish inflammatory bowel disease subtypes: a multicenter cross-sectional study.Xiong Z, Wu P, Zhang Y, Chen J, Shen Y, Yu S, Yuan H, He L, Li Z. Radiological biomarkers reflecting visceral fat distribution help distinguish inflammatory bowel disease subtypes: a multicenter cross-sectional study.Sehgal P, Su S, Zech J, et al. Visceral Adiposity Independently Predicts Time to Flare in Inflammatory Bowel Disease but Body Mass Index Does Not. Inflamm Bowel Dis. 2024; 30 (4): 594–601. DOI: 10.1093/ibd/izad111Sehgal P, Su S, Zech J, et al. Visceral Adiposity Independently Predicts Time to Flare in Inflammatory Bowel Disease but Body Mass Index Does Not. Inflamm Bowel Dis. 2024; 30 (4): 594–601. DOI: 10.1093/ibd/izad111Hyde PN, Kendall KL, Fairman CM, Coker NA, Yarbrough ME, Rossi SJ. Use of B-Mode Ultrasound as a Body Fat Estimate in Collegiate Football Players. J Strength Cond Res. 2016; 30 (12): 3525–3530. DOI: 10.1519/JSC.0000000000001447Hyde PN, Kendall KL, Fairman CM, Coker NA, Yarbrough ME, Rossi SJ. Use of B-Mode Ultrasound as a Body Fat Estimate in Collegiate Football Players. J Strength Cond Res. 2016; 30 (12): 3525–3530. DOI: 10.1519/JSC.0000000000001447Wagner DR, Cafferty EA, Harper SA, Vakula MN. Validity of A-Mode Ultrasound for Estimating Body Fat Percentage of Young Adult Athletes: A Multicomponent Model Study. Med Sci Sports Exerc. 2025; 57 (6): 1239–1245. DOI: 10.1249/MSS.0000000000003651Wagner DR, Cafferty EA, Harper SA, Vakula MN. Validity of A-Mode Ultrasound for Estimating Body Fat Percentage of Young Adult Athletes: A Multicomponent Model Study. Med Sci Sports Exerc. 2025; 57 (6): 1239–1245. DOI: 10.1249/MSS.0000000000003651Neagu M, Neagu A. A Decade of Progress in Ultrasound Assessments of Subcutaneous and Total Body Fat: A Scoping Review. Life (Basel). 2025; 15 (2): 236. Published 2025 Feb 5. DOI: 10.3390/life15020236Neagu M, Neagu A. A Decade of Progress in Ultrasound Assessments of Subcutaneous and Total Body Fat: A Scoping Review. Life (Basel). 2025; 15 (2): 236. Published 2025 Feb 5. DOI: 10.3390/life15020236Donini LM, Busetto L, Bischoff SC. et al. Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement. Obes Facts. 2022; 15 (3): 321–335. DOI: 10.1159/000521241Donini LM, Busetto L, Bischoff SC. et al. Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement. Obes Facts. 2022; 15 (3): 321–335. DOI: 10.1159/000521241Мамутова Э. М., Шептулина А. Ф., Тимофеев Ю. С., Яфарова А. А., Метель- ская В. А., Драпкина О. М. Концентрация иризина, эритроферрона, миостатина и интерлейкина-6 в сыворотке крови у пациентов с ожирением в зависимости от наличия саркопении. Профилактическая медицина. 2025; 28 (2): 67–73.Mamutova EM, Sheptulina AF, Timofeev YuS, Yafarova AA, Metelskaya VA, Drapkina OM. Serum concentrations of irisin, erythroferrone, myostatin and interleukin-6 in obese patients depending on the presence of sarcopenia. Russian Journal of Preventive Medicine. 2025; 28 (2): 67–73. (In Russ.). https://doi.org/10.17116/profmed20252802167El Dimassi S, Gautier J, Zalc V, Boudaoud S, Istrate D. Body Water Volume Estimation Using Bio Impedance Analysis: Where Are We? IRBM. 2024 Jun; 45 (3): 100839. DOI: 10.1016/j.irbm.2024.100839El Dimassi S, Gautier J, Zalc V, Boudaoud S, Istrate D. Body Water Volume Estimation Using Bio Impedance Analysis: Where Are We? IRBM. 2024 Jun; 45 (3): 100839. DOI: 10.1016/j.irbm.2024.100839Batista G, Dorna M, Baima J, de Barros J, Gondo F, Biondi R, Sassaki L, de Paiva Sergio Alberto R. Body Fluids Composition Estimated by Bioelectrical Impedance in Patients With Inflammatory Bowel Diseases [P-081]. Am J Gastroenterol. 2018 Feb; 113: S 19.Batista G, Dorna M, Baima J, de Barros J, Gondo F, Biondi R, Sassaki L, de Paiva Sergio Alberto R. Body Fluids Composition Estimated by Bioelectrical Impedance in Patients With Inflammatory Bowel Diseases [P-081]. Am J Gastroenterol. 2018 Feb; 113: S 19.Fu H, Wang L, Zhang W, Lu J, Yang M. Diagnostic test accuracy of ultrasound for sarcopenia diagnosis: A systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2023; 14 (1): 57–70. DOI: 10.1002/jcsm.13149Fu H, Wang L, Zhang W, Lu J, Yang M. Diagnostic test accuracy of ultrasound for sarcopenia diagnosis: A systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2023; 14 (1): 57–70. DOI: 10.1002/jcsm.13149Kokura Y, Nishioka S, Maeda K, Wakabayashi H. Ultrasound utilized by registered dietitians for body composition measurement, nutritional assessment, and nutritional management. Clin Nutr ESPEN. 2023; 57: 173–180. DOI: 10.1016/j.clnesp.2023.06.026Kokura Y, Nishioka S, Maeda K, Wakabayashi H. Ultrasound utilized by registered dietitians for body composition measurement, nutritional assessment, and nutritional management. Clin Nutr ESPEN. 2023; 57: 173–180. DOI: 10.1016/j.clnesp.2023.06.026Kojima T, Kurachi K, Tatsuta K, et al. Myosteatosis Evaluated Based on Intramuscular Adipose Tissue Content Is a Risk Factor for Postoperative Complications in Crohn's Disease. Inflamm Bowel Dis. 2025; 31 (7): 1851–1860. DOI: 10.1093/ibd/izae247Kojima T, Kurachi K, Tatsuta K, et al. Myosteatosis Evaluated Based on Intramuscular Adipose Tissue Content Is a Risk Factor for Postoperative Complications in Crohn's Disease. Inflamm Bowel Dis. 2025; 31 (7): 1851–1860. DOI: 10.1093/ibd/izae247Bryant RV, Ooi S, Schultz CG et al. Low muscle mass and sarcopenia: common and predictive of osteopenia in inflammatory bowel disease. Aliment Pharmacol Ther. 2015; 41 (9): 895–906. DOI: 10.1111/apt.13156Bryant RV, Ooi S, Schultz CG et al. Low muscle mass and sarcopenia: common and predictive of osteopenia in inflammatory bowel disease. Aliment Pharmacol Ther. 2015; 41 (9): 895–906. DOI: 10.1111/apt.13156

The authors declare that there are no conflicts of interest present.